Ribociclib Survival Data Anchor a Sobering ESMO 2026 for Breast Cancer

For pharmacists caring for patients with breast cancer, the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid delivered one long-awaited answer and several cautionary ones. Adjuvant CDK4/6 inhibition now has an overall survival (OS) benefit behind it. Meanwhile, immunotherapy in hormone receptor (HR)–positive disease and extended endocrine therapy both improved earlier end points without moving survival.

NATALEE: An OS Benefit Emerges at 6 Years

In the 6-year analysis of the phase 3 NATALEE trial (NCT03701334), adding ribociclib (Kisqali; Novartis) to a nonsteroidal aromatase inhibitor (NSAI) improved OS in patients with stage II to III HR-positive/HER2-negative early breast cancer (HR, 0.81; 95% CI, 0.66-0.99). Six-year OS was approximately 91.9% vs 89.7%. The invasive disease-free survival (iDFS) benefit widened from 4.1 percentage points at 5 years to 5.3 at 6 years (HR, 0.74; 95% CI, 0.65-0.85), and breast cancer–specific survival also favored ribociclib (HR, 0.71).¹

Because the curves keep separating after treatment ends, the data strengthen the case for helping patients finish the full 3-year course through adherence follow-up, QTc and liver function monitoring, and drug interaction screening.

KEYNOTE-B49: PFS Without Survival

The phase 3 KEYNOTE-B49 trial (NCT04895358) randomly assigned patients with PD-L1–positive (combined positive score [CPS] of 1 or higher) HR-positive/HER2-negative advanced breast cancer to pembrolizumab (Keytruda; Merck) or placebo plus chemotherapy after progression on endocrine therapy. Median progression-free survival (PFS) was 6.7 vs 6.0 months (HR, 0.74; 95% CI, 0.58-0.95), but final OS showed no benefit (21.0 vs 22.2 months; HR, 1.04; 95% CI, 0.81-1.33).²

For now, adding a checkpoint inhibitor in this setting adds the risk of immune-related toxicity without a proven survival gain.

NSABP B-42: Fewer Recurrences, Same Survival

At a median follow-up of 15.9 years, the final analysis of NRG Oncology/NSABP B-42 (NCT00382070) showed that 5 additional years of letrozole after aromatase inhibitor–based therapy improved disease-free survival (HR, 0.85; 95% CI, 0.76-0.94) and reduced distant recurrence (HR, 0.72; 95% CI, 0.57-0.91), but not OS (HR, 0.92; 95% CI, 0.82-1.05).³ Pharmacists can help patients weigh that benefit against bone loss, arthralgia, and adherence fatigue.

ADCs: One Gain, One Miss

Final OS from the phase 3 OptiTROP-Breast01 trial (NCT05347134) supported sacituzumab tirumotecan (Kelun-Biotech, Merck) over chemotherapy in previously treated advanced triple-negative breast cancer (median, 14.7 vs 9.9 months; HR, 0.60; 95% CI, 0.45-0.80). The trial enrolled only patients in China, and the analysis was descriptive because significance was reached at the interim analysis.⁴

The neoadjuvant TALENT trial (NCT04553770) was less encouraging. Trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo), given alone, with anastrozole, or followed by chemotherapy, produced pathologic complete response rates of approximately 7%, 3%, and 9%, respectively, in HR-positive/HER2-low early breast cancer.⁵

The Takeaway

The breast cancer data from Madrid share a theme: earlier end points do not guarantee longer lives. For pharmacists, that distinction matters at the counter. It shapes how they frame the burden of a 3-year oral regimen, an added immunotherapy, or another 5 years of endocrine therapy for the patients asked to carry it.

REFERENCES

1. Slamon D. Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes. Presented at: European Society for Medical Oncology Congress 2026; October 23-27, 2026; Madrid, Spain. Abstract LBA25.

2. Rugo H. Results from KEYNOTE-B49: a phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC). Presented at: European Society for Medical Oncology Congress 2026; October 23-27, 2026; Madrid, Spain. Abstract LBA51.

3. Mamounas EP, Bandos H, Geyer CE Jr, et al. Final analysis of NRG Oncology/NSABP B-42, a randomized, double-blinded, placebo-controlled trial of extended letrozole in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant therapy with an aromatase inhibitor. Presented at: European Society for Medical Oncology Congress 2026; October 23-27, 2026; Madrid, Spain. Abstract LBA24.

4. Li M. Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: phase III OptiTROP-Breast01. Presented at: European Society for Medical Oncology Congress 2026; October 23-27, 2026; Madrid, Spain. Abstract 4639RO.

5. Hurvitz SA. Final results of TALENT: a neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer. Presented at: European Society for Medical Oncology Congress 2026; October 23-27, 2026; Madrid, Spain. Abstract LBA23.